Qualification & Validation
Qualification & Validation
Quality Assurance
Quality Assurance
Regulatory Affairs
Regulatory Affairs
Clinical
Clinical
Lab Services
Lab Services
Vigilance
Vigilance
Software Solutions & Services
Software Solutions & Services
Tox green
Toxicology
Pharma (2)
Pharma & Biotech
Medical Devices (2)
Medical devices
IVD (2)
In vitro diagnostics
Search QbD Group
  • There are no suggestions because the search field is empty.

MDCG 2022-13 Rev.1 – Designation, Re-assessment, and Notification Process for Conformity Assessment and Notified Bodies

Author Avatar
Kirsten Van Garsse, Authorized Representative Director & Regulatory Affairs Manager
Regulatory Affairs
In Vitro Diagnostics
Medical Devices
Calander_icon

On June 17th, 2024, the Medical Device Coordination Group (MDCG) released a new revision of the guidance to the authorities responsible for notified bodies and joint assessment teams (JATs) when conducting a) assessments of conformity assessment bodies (CABs) that apply for designation of notified bodies (NB) in the field of medical devices and/ or in vitro diagnostic medical devices and b) re-assessment of NBs (MDCG 2022-13 Revision 1).

MDCG 2022-13 Rev.1 – Designation, Re-assessment, and Notification Process for Conformity Assessment and Notified Bodies
0:50

MDCG 2022-13 Revision 1 – Designation, re-assessment and notification of conformity assessment bodies and notified bodies

This guidance is intended for use by Designating Authorities and Joint Assessment Teams to assist them when conducting assessments of Conformity Assessment Bodies applying for designation as NB or when reassessing NB and now includes updates on the conduct of joint assessments relating to extending the scope of designations.

 

 

CTA RA update


 

Discover more expert content

Regulatory update - New updates to MDCG Guidance document released - QbD Group
Regulatory Affairs

New updates to MDCG Guidance document released

The documents are available in the Notified Body section of the MDCG Guidance webpage. The...
Read more
Regulatory Affairs

MDCG 2024-12 released

It includes detailed sections on corrections, root cause analysis, corrective and preventive...
Read more
Regulatory Affairs

Revision of MDCG 2019-13 released

MDCG 2019-13 Rev.1: Guidance on sampling of MDR Class IIa / Class IIb and IVDR Class B / Class C...
Read more
Regulatory Affairs

New EMA FAQ on medicinal products development and assessment involving a CDx

EMA released Q&A on biomarker-guided meds, excluding clinical trial approval and CDx conformity....
Read more
Regulatory Affairs

New EMA Guideline on Environmental Risk Assessment for Human Medicinal Products

New guideline from the European Medicines Agency (EMA) on the Environmental Risk Assessment of...
Read more
Discover all

Stay ahead in life sciences

Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.

Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.

Subscribe to our newsletter
Circles-banner-short